AOD-9604 Metabolic.
Metabolic is developing AOD-9604 for the potential treatment of obesity. By February 2002, phase IIa trials were underway.
Wilding
John
J
Diabetes and Endocrinology Research Group, Clinical Sciences Centre, University Hospital Aintree, Longmoor Lane, Liverpool, L9 7AL, UK. j.p.h.wilding@liv.ac.uk
D000818:Animals; D019440:Anti-Obesity Agents / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D009765:Obesity / Q000188:drug therapy; D010446:Peptide Fragments / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use; D013004:Somatostatin / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use; D013329:Structure-Activity Relationship
C441619:AOD 9604; D019440:Anti-Obesity Agents; D010446:Peptide Fragments; D013004:Somatostatin